Evidence map›Paper›PMID 38655752›Full record

ArticleAmerican journal of hematology2024

GLP-1 agonists and SGLT-2 inhibitors in adults with sickle cell disease.

Ryan Sun, Anand Srivastava, Vimal K Derebail, Jin Han, Robert E Molokie, Victor Gordeuk, Santosh L Saraf

Registry-linked trialOpen access · bronzeAbstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of hematology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07175051 (Targeting the Pathophysiology of Sickle Cell-Related Kidney Disease Using the SGLT2 Inhibitors, Empagliflozin), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07175051 phase2recruitingnot on this mapstarted 2026, after this paper: background citation

Targeting the Pathophysiology of Sickle Cell-Related Kidney Disease Using the SGLT2 Inhibitors, Empagliflozin

TypeinterventionalSponsorUniversity of Illinois at ChicagoRan2026 to 2030Enrolled20ConditionsSickle Cell Anemia (HbSS, or HbSβ-thalassemia0), AlbuminuriaArmsEmpagliflozin (oral)
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. Endothelin receptor antagonism in sickle cell disease: Is the time now?Canadian journal of physiology and pharmacology · 2026
    Review
  4. Management of Kidney Disease with Sickle Cell Disease.Journal of the American Society of Nephrology : JASN · 2025
    Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Ryan SunSickle Cell Center, Division of Hematology & Oncology, University of Illinois Chicago, Chicago, Illinois, USA.
Anand SrivastavaDivision of Nephrology, University of Illinois Chicago, Chicago, Illinois, USA.
Vimal K DerebailUNC Kidney Center, Division of Nephrology and Hypertension, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.ORCID 0000-0002-7662-7497
Jin HanSickle Cell Center, Division of Hematology & Oncology, University of Illinois Chicago, Chicago, Illinois, USA.ORCID 0000-0003-0662-006X
Robert E MolokieSickle Cell Center, Division of Hematology & Oncology, University of Illinois Chicago, Chicago, Illinois, USA.
Victor GordeukSickle Cell Center, Division of Hematology & Oncology, University of Illinois Chicago, Chicago, Illinois, USA.ORCID 0000-0003-4725-7295
Santosh L SarafSickle Cell Center, Division of Hematology & Oncology, University of Illinois Chicago, Chicago, Illinois, USA.ORCID 0000-0002-8584-4194
University of Illinois Chicago · USUniversity of North Carolina at Chapel Hill · US

Funding

Pathways of Cell-Free Hemoglobin in Sickle Cell NephropathyR01HL153161 · NHLBI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI SARAF, SANTOSH · 2020 to 2024
$2.0M
Non-Invasive Imaging Biomarkers to Identify a High-Risk Chronic Kidney Disease PhenotypeK23DK120811 · NIDDK · UNIVERSITY OF ILLINOIS AT CHICAGO · PI SRIVASTAVA, ANAND · 2020 to 2024
$1.0M
NHLBI NIH HHS HL153161NHLBI NIH HHS R01 HL153161NIDDK NIH HHS K23 DK120811
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Anemia, Sickle CellSodium-Glucose Transporter 2 InhibitorsAdultDiabetes Mellitus, Type 2FemaleGlucagon-Like Peptide 1HumansHypoglycemic AgentsMaleMiddle AgedSodium-Glucose Transporter 2Glucagon-Like Peptide 1Hypoglycemic AgentsSodium-Glucose Transporter 2Sodium-Glucose Transporter 2 Inhibitors

Identifiers

PMID38655752
PMCPMC12556597
OpenAlexW4395076190

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.